Issue link: https://optometricmanagementsupplements.epubxp.com/i/571093
S 22 S E P T E M B E R 2 0 1 5 • O P T O M E T R I C M A N A G E M E N T . C O M days as doctors lined up to purchase the system and distribu- tors lobbied to get distribution rights for their countries. First OCT with Retina & Cornea Applications Te RTVue system was the frst OCT to have both retina and cornea applications in a single device, providing true imaging and analysis of the anterior chamber by a poste- rior OCT device. Today, all Optovue OCT systems include both posterior and anterior scanning capabilities. First Ganglion Cell Complex Analysis Measuring just the three layers that make up the gan- glion cell complex was not a new idea; however, until the RTVue was introduced, no device had efectively isolated the three layers and mapped them to follow changes in the thickness of the anatomy. Shown by dozens of ARVO ab- stracts to ofen precede measurable changes in the para- papillary RNFL, evaluation of the GCC has moved the potential detection of glaucomatous structural changes earlier in the glaucoma continuum. First OCT Platform Designed for Cost-Efective Portability Te iVue SD-OCT brought advanced OCT technology to a broader market in 2010, breaking the price barrier by 35% or more. iVue was designed to be compact and portable while still providing the specifc scans that most eye care profes- sionals for both posterior and anterior assessment. MEET YOUR OCT SPECIALIST S P O N S O R E D B Y O P T O V U E IT BEGAN AS A CLOSELY GUARDED SECRET… I N THE EARLY DAYS, Optovue operated com- pletely under the radar. In fact, the mere exis- tence of the company remained a closely guard- ed secret until one week before the American Academy of Ophthalmology meeting in 2006. When Optovue did make its debut, more than 350 clinicians attended the company's symposium to hear doctors Yasuo Tano, Jay Duker, Joel Schuman and David Huang speak about the device they had used in confdence for over a year. At that inaugural congress, Optovue sold over $1 million worth of RTVue units, the frst FDA-cleared Spectral Domain OCT. Since the introduction of the RTVue SD-OCT, Optovue has continued to stay ahead of the curve by pushing the tech- nology into places that it had not yet gone. Te founders and development team at Optovue have been developing devices based on OCT technology since 1993 and are among the most experienced people in OCT product development. Tis specialized knowledge and understanding of the technology fuels Optovue's innovative spirit and gives the company a unique ability to incorporate novel ideas and functionality into its OCT systems at an incredibly rapid pace. …FOLLOWED BY A SERIES OF "FIRSTS" THAT ARE IMPROVING EYE HEALTH CARE… As the only company dedicated exclusively to OCT, Optovue has pioneered numerous innovations that have changed the way that eye care professionals care for the health of their patients' eyes while making the technology more accessible to practices worldwide. First Spectral Domain OCT Optovue launched the frst FDA-cleared Spectral Domain OCT, the RTVue, at the American Academy of Ophthalmol- ogy meeting in 2006. Te device caused a sensation for four Jay Wei Founder and CEO Optovue OPTOME TRIC MANAGEMENT CORPORATE PROFILE Optovue introduced the frst SD-OCT in 2006.